Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Prospective Phase II Clinical Trial Using Chidamide, Tislelizumab, and Pegaspargase (CTP regimen) in Combination with Radiotherapy As First-Line Treatment in High-Risk Stages I and II of Extranodal NK/T-Cell Lymphoma

Yajun Li, Ruolan Zeng, Yizi He, Caiqin Wang, Chen Xia, Zhongtai Wang, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 6394.

https://doi.org/10.1182/blood-2024-202471

Published: 2024

Journal Articles

Progression of Disease within 24 Months (POD24) Based Prognostic Signature: A New Method for Personalized Risk Assessment in Patients with Mantle Cell Lymphoma

Yizi He, Caiqin Wang, Yajun Li, Ruolan Zeng, Chen Xia, Yixue Li, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 6288.

https://doi.org/10.1182/blood-2024-202252

Published: 2024

Journal Articles

Brentuximab Vedotin-Based Treatment in Patients with CD30-Positive Lymphoma: A Retrospective Analysis

Yixue Li, Ruolan Zeng, Chen Xia, Yajun Li, Yizi He, Caiqin Wang, Hui Zhou

Blood (2024) 144 (Supplement 1): 6465.

https://doi.org/10.1182/blood-2024-204718

Published: 2024

Journal Articles

Prophylaxis with Thiotepa and High-Dose Methotrexate Showed Low CNS Relapse Rate in Diffuse Large B-Cell Lymphoma with High Risk of CNS Relapse

Ruolan Zeng, Zhou Ouyang, Yajun Li, Yizi He, Caiqin Wang, Chen Xia, Zhongtai Wang, Yixue Li, Yinhua Liu, Weiqiang Tang, Qianying Ouyang, Liang Liang, Chang Su, Guige Lu, Xueting Zhu, Qianyu Hu, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 6460.

https://doi.org/10.1182/blood-2024-202812

Published: 2024

Journal Articles

Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

Xin Li, Jia Wei, Dong-feng Zeng, Shu-nan Qi, Bingzong Li, Wei Guo, Li Wang, Yajun Li, Xudong Zhang, Yong Yang, Shukai Qiao, Yan Zeng, Yunfei Song, Jing-wen Wang, Jian-min Ma, Liang Wang

Blood (2024) 144 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2024-206489

Published: 2024

Journal Articles

Sintilimab Plus Gemcitabine, Cisplatin, and Dexamethasone As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma：a Multicenter Retrospective Study

Blood (2024) 144 (Supplement 1): 6355.

https://doi.org/10.1182/blood-2024-194674

Published: 2024

Journal Articles

Clinical Applications of Circulating Tumor DNA in the Diagnosis and Prognostic Stratification of Mantle Cell Lymphoma

Zhou Ouyang, Yajun Li, Ruolan Zeng, Yizi He, Caiqin Wang, Chen Xia, Zhongtai Wang, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 6197.

https://doi.org/10.1182/blood-2024-201575

Published: 2024

Journal Articles

BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

Ningjing Lin, Tingting Du, Hui Zhou, Yajun Li, Liang Wang, Xiaomeng Dong, Haochuan Zheng, Jingtao Lu, Mi Tang, Jihua Wu, Wei Zhu, Yuqin Song, Jun Zhu

Blood (2024) 144 (Supplement 1): 4175.

https://doi.org/10.1182/blood-2024-206674

Published: 2024

Journal Articles

The Efficacy and Safty of Chidamide and Azacitidine Combined with Chemotherapy As a First-Line Treatment in T Follicular Helper Lymphomas: A Comprehensive Retrospective Study

Chen Xia, Yajun Li, Zhongyi Sun, Lijun Huang, Ruolan Zeng, Yizi He, Caiqin Wang, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 1675.

https://doi.org/10.1182/blood-2024-200882

Published: 2024

Journal Articles

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV + Non-Hodgkin Lymphoma (NHL)

Lin Gui, Keshu Zhou, Ting Liu, Yan Qin, Hongmei Jing, Wenyu Li, Yajun Li, Wenrong Huang, Zhen Wang, Xiuhua Sun, Quan Li, Faming Zhang, Henry Li, Lei Zhang, Peng Sun, Xinbao Gao, Yuankai Shi

Blood (2024) 144 (Supplement 1): 1741.

https://doi.org/10.1182/blood-2024-194771

Published: 2024

Journal Articles

Novel Role of Chidamide in Tumor-Associated Macrophages Reprogramming and Immunotherapy Enhancement through RNA Splicing

Caiqin Wang, Yizi He, Yajun Li, Ruolan Zeng, Zhiming Li, Ling Xiao, Hui Zhou

Blood (2024) 144 (Supplement 1): 1413.

https://doi.org/10.1182/blood-2024-204698

Published: 2024

Journal Articles

Combining Selinexor with R-CHOP in the Treatment of Newly Diagnosed High-Risk (IPI 3-5) GCB Subtype DLBCL Patients: A Multicenter, Open Label Phase 2 Study

Zhiming Li, Hang Yang, Yanxue Yin, Yajun Li, Xue Gao, Peng Sun, Yu Wang, Lu Zhang, Hui Zhou, Keshu Zhou, Jay Mei

Blood (2023) 142 (Supplement 1): 6240.

https://doi.org/10.1182/blood-2023-181503

Published: 2023

Journal Articles

Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly-Diagnosed Advanced, Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: A Multicenter, Phase 2 Cohort of the Open-Label Spirit Study

Qingqing Cai, Panpan Liu, Yi Xia, Jun Cai, Huiqiang Huang, Zhiming Li, Hui Zhou, Yajun Li, Hanyu Wang, Ying Huang, Gao Yan, Xueyi Pan

Blood (2022) 140 (Supplement 1): 2299–2301.

https://doi.org/10.1182/blood-2022-168457

Published: 2022

Journal Articles

Safety and Preliminary Efficacy of Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen As First-Line Treatment for Patients with Advanced Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: An Open-Label, Multicenter, Phase 2 Study

Qingqing Cai, PhD, Huiqiang Huang, MDPhD, Panpan Liu, MD PhD, Hui Zhou, MD PhD, Yajun Li, MD PhD, Yujing Zhang, MD PhD, Lixia Lu, MD PhD, Yan Gao, MD PhD, Xuanye Zhang, MDPhD, Yi Xia, MD PhD, Jun Cai, BMBS, Ning Su, MM, Shuyun Ma, MM, Hang Yang, MD PhD, Yu Fang, BMBS

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-136949

Published: 2020

NARROW

A Prospective Phase II Clinical Trial Using Chidamide, Tislelizumab, and Pegaspargase (CTP regimen) in Combination with Radiotherapy As First-Line Treatment in High-Risk Stages I and II of Extranodal NK/T-Cell Lymphoma

Progression of Disease within 24 Months (POD24) Based Prognostic Signature: A New Method for Personalized Risk Assessment in Patients with Mantle Cell Lymphoma

Brentuximab Vedotin-Based Treatment in Patients with CD30-Positive Lymphoma: A Retrospective Analysis

Prophylaxis with Thiotepa and High-Dose Methotrexate Showed Low CNS Relapse Rate in Diffuse Large B-Cell Lymphoma with High Risk of CNS Relapse

Multicenter Retrospective Cohort Study of 694 Patients with Ocular Adnexal Marginal Zone B-Cell Lymphoma on Behalf of the Chinese Ocular Lymphoma Collaborative Group (COLCG)

Sintilimab Plus Gemcitabine, Cisplatin, and Dexamethasone As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma：a Multicenter Retrospective Study

Clinical Applications of Circulating Tumor DNA in the Diagnosis and Prognostic Stratification of Mantle Cell Lymphoma

BR105 Is a Novel Anti-Sirpα Monoclonal Antibody That Demonstrates a Favorable Safety Profile and Potent Anti-Tumor Efficacy in Patients with Relapsed/Refractory Lymphoid Malignancies: Preliminary Results from a Phase I Study

The Efficacy and Safty of Chidamide and Azacitidine Combined with Chemotherapy As a First-Line Treatment in T Follicular Helper Lymphomas: A Comprehensive Retrospective Study

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV + Non-Hodgkin Lymphoma (NHL)

Novel Role of Chidamide in Tumor-Associated Macrophages Reprogramming and Immunotherapy Enhancement through RNA Splicing

Combining Selinexor with R-CHOP in the Treatment of Newly Diagnosed High-Risk (IPI 3-5) GCB Subtype DLBCL Patients: A Multicenter, Open Label Phase 2 Study

Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly-Diagnosed Advanced, Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: A Multicenter, Phase 2 Cohort of the Open-Label Spirit Study

Safety and Preliminary Efficacy of Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen As First-Line Treatment for Patients with Advanced Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: An Open-Label, Multicenter, Phase 2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only